Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
REDWOOD CITY, Calif., April 25, 2018 (GLOBE NEWSWIRE) -- ARMO BioSciences, Inc. (Nasdaq:ARMO), a late-stage immuno-oncology company, today announced three abstracts on pegilodecakin (AM0010), a...
-
REDWOOD CITY, Calif., April 03, 2018 (GLOBE NEWSWIRE) -- ARMO BioSciences, Inc. (Nasdaq:ARMO), a late-stage immuno-oncology company, today announced that Martin Oft, M.D., Senior Vice President,...
-
First Patient Enrolled in CYPRESS 1 Trial in Non-Small Cell Lung Cancer REDWOOD CITY, Calif., April 02, 2018 (GLOBE NEWSWIRE) -- ARMO BioSciences, Inc. (Nasdaq:ARMO), a late-stage immuno-oncology...
-
REDWOOD CITY, Calif., March 29, 2018 (GLOBE NEWSWIRE) -- ARMO BioSciences, Inc. (Nasdaq:ARMO), a late-stage immuno-oncology company, today announced enrollment of its first patient in CYPRESS 2, a...
-
Data Monitoring Committee Recommends Study Proceed Without Modification REDWOOD CITY, Calif., March 26, 2018 (GLOBE NEWSWIRE) -- ARMO BioSciences, Inc. (Nasdaq:ARMO), a late-stage immuno-oncology...